Bacteria Containment FDA Approval In-Vitro 
XTalks
AUGUST 9, 2023
a leader in developing therapeutic solutions for common diseases with limited treatment alternatives, has secured approval from the US Food and Drug Administration (FDA) for its drug, Xdemvy (lotilaner ophthalmic solution) 0.25%. California-based Tarsus Pharmaceuticals Inc., What Is Demodex Blepharitis?
Drug Discovery World
SEPTEMBER 28, 2023
This is likely in part because their byproduct, lactic acid, is known to inhibit pathogenic bacteria 25. And, in the endometrium, a decrease in Lactobacillus may affect embryo attachment and promote the growth of detrimental bacteria. This article will focus on one such area of great unmet need and promise: women’s health.
Expert insights. Personalized for you.
98 
Let's personalize your content